文献速递青光眼眼底病与葡萄膜炎

糖尿病患者小梁切除术:结膜下MMC联合或不联合玻璃体腔注射贝伐珠单抗

Trabeculectomy in patients with diabetes: subconjunctival Mitomycin C with or without intravitreal bevacizumab.
PubMed 文献 · Br J Ophthalmol · 2020-12-16

结果显示联合组术后12个月眼压和抗青光眼药物数量均更低,但两组累积成功率无统计学差异。

要点

  • 联合组12个月眼压10.1±2.8 mmHg,单用MMC组15.2±6.9 mmHg,组间P=0.001。
  • 联合组12个月抗青光眼药物数0.3±0.8,单用MMC组1.0±1.2,P=0.02。
  • 12个月累积成功率联合组89.3%、单用MMC组78.6%,P=0.27无统计学差异。

核心结论

  • 在需行原发性小梁切除术的糖尿病患者中,玻璃体腔注射贝伐珠单抗联合结膜下MMC较单用结膜下MMC可获得更低眼压和更少抗青光眼药物。

研究设计与样本

  • 所有患者完成至少1年随访,主要结局为眼压、抗青光眼药物数量、滤过泡形态和成功概率。

主要发现

  • 联合组1年平均眼压从25.2±12.0 mmHg降至10.1±2.8 mmHg,单用MMC组从26.4±11.6 mmHg降至15.2±6.9 mmHg(均P<0.001)。
  • 术后12个月联合组眼压显著低于单用MMC组(P=0.001)。
  • 12个月时联合组抗青光眼药物数为0.3±0.8,单用MMC组为1.0±1.2(P=0.02)。
  • 12个月累积成功概率联合组89.3%、单用MMC组78.6%,差异无统计学意义(P=0.27)。

关键数值与推荐

  • 完全成功定义为不用抗青光眼药物且眼压≤18 mmHg或<15 mmHg并较术前下降至少20%;条件成功为达到上述眼压标准但需用抗青光眼药物;总成功为完全成功与条件成功之和。

临床怎么用

  • 对无新生血管性青光眼的糖尿病患者,小梁切除术中联合玻璃体腔贝伐珠单抗与结膜下MMC可能有助于降低术后眼压和减少抗青光眼药物使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the success of Mitomycin C (MMC) augmented trabeculectomy with or without intravitreal bevacizumab in patients with diabetes without neovascular glaucoma. METHODS: Fifty-six patients with diabetes who needed trabeculectomy were randomised to either combination of 2.5 mg intravitreal bevacizumab and subconjunctival MMC (group A, 28 eyes) or subconjunctival MMC alone (group B, 28 eyes). The main outcome measures were intraocular pressure (IOP), number of antiglaucoma medications, bleb morphology and success probability. Surgical success was defined as complete according to two levels of IOP (≤18 and <15 mm Hg) and at least 20% reduction from preoperative IOP without antiglaucoma medications and qualified as complete success but with antiglaucoma medications. Total success was the sum of complete and qualified success. RESULTS: The mean age was 65.2±12.9 and 67.4±10.2 years in groups A and B, respectively (p=0.50). All patients completed at least 1 year of follow-up. The mean 1-year IOP decreased from 25.2±12.0 mm Hg to 10.1±2.8 in group A and from 26.4±11.6 mm Hg to 15.2±6.9 in group B (all p<0.001). Overall, postoperative IOP measurement was statistically significantly lower in group A at month 12 (p=0.001). The number of medications in groups A and B at month 12 was 0.3±0.8 and 1.0±1.2, respectively (p=0.02). The cumulative probability of success at month 12 was not statistically significant (89.3% group A, 78.6% group B; p=0.27). CONCLUSION: In patients with diabetes with primary trabeculectomy, combined administration of intravitreal bevacizumab and subconjunctival MMC resulted in lower IOP and number of antiglaucoma medication compared with subconjunctival MMC alone.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nilforushan N, Es'haghi A, Miraftabi A, et al. Trabeculectomy in patients with diabetes: subconjunctival Mitomycin C with or without intravitreal bevacizumab. Br J Ophthalmol. 2020. PMID: 33328187. doi:10.1136/bjophthalmol-2020-317324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。